Glaukos

Yahoo Finance • 2 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 D... Full story

Yahoo Finance • 5 months ago

Should You Be Bullish on Glaukos Corporation (GKOS)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared t... Full story

Yahoo Finance • 5 months ago

Glaukos Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Glaukos (NYSE:GKOS) Second Quarter 2024 Results Key Financial Results Revenue: US$95.7m (up 19% from 2Q 2023). Net loss: US$53.9m (loss widened by 64% from 2Q 2023). US$1.06 loss per share (further deteriorated from US$0.68 loss in 2Q 20... Full story

Yahoo Finance • 10 months ago

Insider Sell: Glaukos Corp's President & COO Joseph Gilliam Sells 1,512 Shares

On February 12, 2024, Joseph Gilliam, President & COO of Glaukos Corp, executed a sale of 1,512 shares of the company. The transaction was filed with the SEC and can be found in the official documentation. Glaukos Corp is a medical techno... Full story

Yahoo Finance • last year

Glaukos Announces Participation in Stifel Healthcare Conference

ALISO VIEJO, Calif., November 07, 2023--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal... Full story

Yahoo Finance • last year

These 2 Soaring Stocks Finished the Week Strong

The upward momentum in the stock market this week ran out of steam on Friday afternoon, as the Nasdaq Composite (NASDAQINDEX: ^IXIC) and S&P 500 (SNPINDEX: ^GSPC) gave up early gains to close slightly lower. Aehr Test Systems (NASDAQ: AEHR... Full story

Yahoo Finance • 2 years ago

Glaukos Submits New Drug Application to U.S. FDA for iDose TR

ALISO VIEJO, Calif., February 27, 2023--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal... Full story

Yahoo Finance • 2 years ago

15 Small Innovative Companies According to the Media

In this piece, we will take a look at the fifteen small innovative companies according to the media. For more small and innovative companies, head on over to 5 Small Innovative Companies According to the Media. Innovation is the bedrock o... Full story

Yahoo Finance • 2 years ago

15 Largest Ophthalmology Companies in the World

In this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompa... Full story

Yahoo Finance • 3 years ago

Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium

SAN CLEMENTE, Calif., May 20, 2022--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal dise... Full story

Yahoo Finance • 3 years ago

Glaukos Corporation Announces First Quarter 2022 Financial Results

SAN CLEMENTE, Calif., May 04, 2022--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal dise... Full story